BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 10, 2008
 |  BioCentury  |  Strategy

Focus pays off for Serenex

By acquiring Serenex Inc. for an undisclosed sum, Pfizer Inc. gets one of only two oral heat shock protein 90 inhibitors in the clinic for cancer. As a bonus, the pharma company also gets Serenex's matrix technology that identifies proteins in the purine-binding proteome, and a library of about 5,000 purine-binding proteins, including Hsp90s.

Hsp90 is a molecular chaperone that regulates the folding and degradation of proteins involved in cell growth and survival. These signaling proteins play key roles in cancer, inflammation and neurodegenerative diseases.

"Our singular focus on Hsp90 was a practical one," Steven Hall, SVP of R&D at Serenex, told BioCentury. "We are a small company - the research group is about 20 people. We were interested in moving a compound from the initial hit identification to the clinic as rapidly as possible, so we focused our resources...

Read the full 697 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >